Pages that link to "Q40114307"

The following pages link to Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model (Q40114307):

Displaying 46 items.

• Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis (Q26865533) (← links)
• r84, a novel therapeutic antibody against mouse and human VEGF with potent anti-tumor activity and limited toxicity induction (Q27321768) (← links)
• Clinical correlates of common corneal neovascular diseases: a literature review (Q28257676) (← links)
• Phosphorylation of Akt and ERK1/2 is required for VEGF-A/VEGFR2-induced proliferation and migration of lymphatic endothelium (Q28741586) (← links)
• The Fate of the Tumor in the Hands of Microenvironment: Role of TAMs and mTOR Pathway. (Q33364555) (← links)
• Successful inhibition of tumor development by specific class-3 semaphorins is associated with expression of appropriate semaphorin receptors by tumor cells (Q33372124) (← links)
• Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer (Q33514852) (← links)
• Inflammation induces lymphangiogenesis through up-regulation of VEGFR-3 mediated by NF-kappaB and Prox1. (Q33597563) (← links)
• GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer (Q33645920) (← links)
• Bu Fei Decoction attenuates the tumor associated macrophage stimulated proliferation, migration, invasion and immunosuppression of non-small cell lung cancer, partially via IL-10 and PD-L1 regulation (Q33788049) (← links)
• Lymphangiogenesis and lymphatic metastasis in breast cancer (Q33940058) (← links)
• Anti‐VEGF Therapy in Breast and Lung Mouse Models of Cancers (Q34284723) (← links)
• Overexpression of the RNA binding protein HuR impairs tumor growth in triple negative breast cancer associated with deficient angiogenesis (Q34583152) (← links)
• CXM: a new tool for mapping breast cancer risk in the tumor microenvironment (Q34586307) (← links)
• Synergy of Nab-paclitaxel and Bevacizumab in Eradicating Large Orthotopic Breast Tumors and Preexisting Metastases (Q34763649) (← links)
• Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates (Q34972161) (← links)
• Vascular endothelial growth factor receptor-2 promotes the development of the lymphatic vasculature (Q34984742) (← links)
• Breast Tumor Angiogenesis and Tumor-Associated Macrophages: Histopathologist's Perspective (Q35055683) (← links)
• MicroRNA-31 controls G protein alpha-13 (GNA13) expression and cell invasion in breast cancer cells (Q35233115) (← links)
• Macrophages in tumor microenvironments and the progression of tumors (Q36065902) (← links)
• Macrophage-mediated lymphangiogenesis: the emerging role of macrophages as lymphatic endothelial progenitors (Q36198192) (← links)
• Novel model for basaloid triple-negative breast cancer: behavior in vivo and response to therapy (Q36343773) (← links)
• Hypoxia increases breast cancer cell-induced lymphatic endothelial cell migration. (Q36528217) (← links)
• Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy (Q36661727) (← links)
• Understanding lymphangiogenesis in knockout models, the cornea, and ocular diseases for the development of therapeutic interventions. (Q36808641) (← links)
• Lymphatic metastasis in breast cancer: importance and new insights into cellular and molecular mechanisms (Q36994267) (← links)
• Liver regeneration and tumor stimulation--a review of cytokine and angiogenic factors. (Q37052713) (← links)
• Drug insight: antiangiogenic therapies for gastrointestinal cancers--focus on monoclonal antibodies (Q37125935) (← links)
• Use of low-molecular-weight heparin to decrease mortality in mice after intracardiac injection of tumor cells. (Q37243800) (← links)
• The relationship between lymphatic vascular density and vascular endothelial growth factor A (VEGF-A) expression with clinical-pathological features and survival in pancreatic adenocarcinomas (Q37277702) (← links)
• VEGF and pleiotrophin modulate the immune profile of breast cancer (Q37328378) (← links)
• Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation (Q37863369) (← links)
• Novel aspects of corneal angiogenic and lymphangiogenic privilege. (Q37681157) (← links)
• Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? (Q37883011) (← links)
• Advances in the research on lymphangiogenesis in carcinoma tissues (Review) (Q38042424) (← links)
• S1P Provokes Tumor Lymphangiogenesis via Macrophage-Derived Mediators Such as IL-1β or Lipocalin-2. (Q38626918) (← links)
• VEGFA Involves in the Use of Fluvastatin and Zoledronate Against Breast Cancer (Q38661111) (← links)
• LyP-1-conjugated doxorubicin-loaded liposomes suppress lymphatic metastasis by inhibiting lymph node metastases and destroying tumor lymphatics (Q39474357) (← links)
• Immunotherapy of head and neck cancer: current and future considerations (Q39955461) (← links)
• Unveiling the role of tumor reactive stroma in cholangiocarcinoma: an opportunity for new therapeutic strategies (Q42272472) (← links)
• High expression of GNA13 is associated with poor prognosis in hepatocellular carcinoma (Q42363972) (← links)
• Combination therapy with short interfering RNA vectors against VEGF-C and VEGF-A suppresses lymph node and lung metastasis in a mouse immunocompetent mammary cancer model. (Q53464008) (← links)
• Metabotropic glutamate receptor-1 regulates inflammation in triple negative breast cancer (Q58098917) (← links)
• Serum levels of vascular endothelial growth factor in gastric cancer patients (Q83549927) (← links)
• Lymphatic Endothelial Cell Progenitors in the Tumor Microenvironment (Q89631300) (← links)
• Hypoxia: Overview on Hypoxia-Mediated Mechanisms with a Focus on the Role of HIF Genes (Q91812815) (← links)